Endpoints News devoted its weekly roundup on October 17 to a question the Alzheimer’s field keeps circling: whether a cheap, safe, widely taken oral drug could do for dementia prevention what statins did for heart attacks. The framing is aspirational, not a result. No cholesterol drug has shown it can prevent Alzheimer’s, and the randomised evidence for statins themselves on cognition is negative to neutral. What has changed is that the hypothesis now has dedicated trials and human biomarker data behind it, rather than epidemiology alone.
The most advanced test belongs to NewAmsterdam Pharma. Its CETP inhibitor obicetrapib, developed to lower LDL cholesterol, is now being evaluated in SPINOZA, a Phase 2b randomised, double blind, placebo controlled trial in approximately 400 adults aged 55 to 85 with preclinical Alzheimer’s disease, meaning biomarker evidence of pathology with little or no cognitive impairment. Participants receive obicetrapib 10 milligrams or placebo, and the primary endpoint is the change at week 52 in plasma p-tau217, a blood biomarker of Alzheimer’s pathology. The first participant was dosed in late September.
The trial exists because of a prespecified biomarker analysis inside BROADWAY, NewAmsterdam’s cardiovascular outcomes program. In that analysis, obicetrapib significantly reduced p-tau217 levels in the full analysis set of 1,515 participants and in the 367 carriers of the ApoE4 risk gene. In the highest risk ApoE4/E4 subgroup, p-tau217 fell 20.5 percent against placebo over 12 months, though that subgroup numbered only 29 people. Biomarker movement of that kind is a reason to run SPINOZA; it is not evidence that dementia was delayed or prevented in anyone.
The other half of the Endpoints item, Arrowhead’s injectable ARO-MAPT lowering tau by an average of 73 percent at the highest dose in healthy volunteers, was reported in full in this site’s October 15 edition and is not repeated here. The two programs mark the fork in the field: prevention with a repurposed metabolic pill on one side, and direct suppression of tau production with a quarterly injection on the other.
For investors the discipline is endpoints. SPINOZA reads out on a blood biomarker over 52 weeks in people without symptoms, so even a clean win leaves the clinical question, whether cognition is preserved, for a much larger and longer trial. The statin analogy cuts both ways: statins earned their prevention claim from outcomes trials in tens of thousands of patients, and Alzheimer’s prevention will be held to the same standard.